Knockdown of eukaryotic translation initiation factor 3 subunit B inhibits cell proliferation and migration and promotes apoptosis by downregulating WNT signaling pathway in acute myeloid leukemia.

Knockdown of eukaryotic translation initiation factor 3 subunit B inhibits cell proliferation and migration and promotes apoptosis by downregulating WNT signaling pathway in acute myeloid leukemia. Int J Clin Exp Pathol. 2020;13(1):99-106 Authors: Feng Y, Wu L Abstract The study aimed to investigate the effect of eukaryotic translation initiation factor 3 subunit B (EIF3B) on cell proliferation, migration, and apoptosis as well as the underlying mechanism in acute myeloid leukemia (AML). EIF3B expression was detected in AML-193, HL-60, OCI-AML2, and KG-1 cell lines and human primary bone marrow mononuclear cells (BMMC). EIF3B knockdown was realized by transfecting EIF3B ShRNA plasmids, and EIF3B knockdown and WNT2 overexpression were established by transfecting EIF3B ShRNA plasmids and WNT2 overexpression plasmids into KG-1 cells. The effect of EIF3B knockdown, and EIF3B knockdown plus WNT2 overexpression on cell proliferation, apoptosis, migration, glycogen synthase kinase 3B (GSK3B) and catenin beta 1 (CTNNB1) was assessed. EIF3B mRNA and protein expression were higher in AML-193, OCL-AML2 and KG-1 cell lines, but unchanged in the HL-60 cell line compared with human primary BMMC. The expression of WNT2 was decreased by EIF3B downregulation, while it had no effect on EIF3B expression. As for cell activities, EIF3B knockdown inhibited the cell proliferation and migration but promoted apoptosis by inhibiting WNT2 expression. In addition, EIF3B knockdown d...
Source: International Journal of Clinical and Experimental Pathology - Category: Pathology Authors: Tags: Int J Clin Exp Pathol Source Type: research

Related Links:

Publication date: 2020Source: Leukemia Research Reports, Volume 13Author(s): Salah Aref, Emaad Azmy, Lamiaa Ibrahim, Mohamed Sabry, Mohamed El Agdar
Source: Leukemia Research Reports - Category: Hematology Source Type: research
(Purdue University) A $1,999,998 SBIR Phase I/II grant from the National Institute of Cancer to KinaRx LLC, a Purdue University-affiliated startup, will help fast-track to human trials a novel platform aimed at treating relapse for acute myeloid leukemia and other diseases.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Here, we report a unique acute myeloid leukemia (AML) bone marrow-derived mesenchymal stem cell (MSC) with both mesenchymal and endothelial potential, which we have named Mesenchymal Cancer Stem Cells (MCSCs)....
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research
Blood Cancer Journal, Published online: 03 June 2020; doi:10.1038/s41408-020-0330-5A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
AbstractPurpose of ReviewNucleophosmin (NPM1) mutations are encountered in myeloid neoplasia and are present in ~  30% of de novo acute myeloid leukemia cases. This review summarizes features of mutantNPM1-related disease, with a particular emphasis on recent discoveries relevant to disease monitoring, prognostication, and therapeutic intervention.Recent FindingsRecent studies have shown thatHOX/MEIS gene overexpression is central to the survival ofNPM1-mutated cells. Two distinct classes of small molecule drugs, BH3 mimetics and menin-MLL interaction inhibitors, have demonstrated exquisite leukemic cell toxicity in...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
Conclusion: RUNX1-mutated AML and MDS are associated with a different complex co-mutation cluster. Some co-mutations have certain influence on the clinical feature and CR rate in the context of RUNX1 mutation. PMID: 32476595 [PubMed - in process]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Researchers at Mount Sinai have discovered that human acute myeloid leukemia (AML) stem cells are dependent on a transcription factor known as RUNX1, potentially providing a new therapeutic target to achieve lasting remissions or even cures for a disease in which medical advances have been limited.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Double knockout of the two miR-15/16 loci in mouse resulted in the development of acute myeloid leukemia (AML). This result suggested that, at least, a fraction of human AMLs could be due to a similar mechanism. We analyzed the role of the two miR-15/16 clusters in 93 myelodysplastic syndrome (MDS)...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Biological Sciences Source Type: research
by Stephen P. Wood, MS, ACNP-BC I stood facing the iPad attached to a rolling stand punching in the phone number of the young granddaughter of my intensive care unit patient. He arrived less than twenty-four hours before. I had taken the call the day before from the outside hospital emergency department and the story was grim. This was a seventy-six-year-old male who had acute myeloid leukemia, hypertension, as well as a history of congestive heart failure. He had been sick for the past two days with a fever, a cough and weakness.…
Source: blog.bioethics.net - Category: Medical Ethics Authors: Tags: End of Life Care Featured Posts Health Care Public Health #bioethicsontheground #covid19 #diaryofaplagueyear COVID-19 Source Type: blogs
Contributors : Hanene Djamai ; Jeannig Berrou ; M élanie Dupont ; Marie-Magdelaine Coudé ; Marc Delord ; Emmanuelle Clappier ; Anna Kaci ; Emmanuel Raffoux ; Raphaël Itzykson ; Caroline Berthier ; Hugues de Thé ; André Baruchel ; Claude Gardin ; Hervé Dombret ; Thorsten BraunSeries Type : Expression profiling by arrayOrganism : Homo sapiensAcute Myeloid Leukemia (AML) is frequently associated with mutations of NPM1 (NPM1c+) and even if considered to be of better prognosis for younger patients, relapse is frequent and outcome remains poor for elder patients with a need for novel treat...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Leukemia | Pathology | Study